Economics of Beta-Cell Replacement Therapy
Purpose of Review: Type 1 diabetes impacts 1.3 million people in the USA with a total direct lifetime medical cost of $133.7 billion. Management requires a mix of daily exogenous insulin administration and frequent glucose monitoring. Decision-making by the individual can be burdensome. Recent Findi...
| Main Authors: | , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
Springer Science and Business Media LLC
2020
|
| Online Access: | https://hdl.handle.net/1721.1/128519 |
| _version_ | 1826199814139805696 |
|---|---|
| author | Bandeiras, Cátia Hwa, Albert J. Cabral, Joaquim M. S. Ferreira, Frederico Castelo Finkelstein, Stan Neil Gabbay, Robert A. |
| author2 | Massachusetts Institute of Technology. Institute for Data, Systems, and Society |
| author_facet | Massachusetts Institute of Technology. Institute for Data, Systems, and Society Bandeiras, Cátia Hwa, Albert J. Cabral, Joaquim M. S. Ferreira, Frederico Castelo Finkelstein, Stan Neil Gabbay, Robert A. |
| author_sort | Bandeiras, Cátia |
| collection | MIT |
| description | Purpose of Review: Type 1 diabetes impacts 1.3 million people in the USA with a total direct lifetime medical cost of $133.7 billion. Management requires a mix of daily exogenous insulin administration and frequent glucose monitoring. Decision-making by the individual can be burdensome. Recent Findings: Beta-cell replacement, which involves devices protecting cells from autoimmunity and allo-rejection, aims at restoring physiological glucose regulation and improving clinical outcomes in patients. Given the significant burden of T1D in the healthcare systems, cost-effectiveness analyses can drive innovation and policymaking in the area. Summary: This review presents the health economics analyses performed for donor-derived islet transplantation and the possible outcomes of stem cell-derived beta cells. Long-term cost-effectiveness of islet transplantation depends on the engraftment of these transplants, and the expenses and thresholds assumed by healthcare systems in different countries. Early health technology assessment analyses for stem cell-derived beta-cell replacement suggest manufacturing optimization is necessary to reduce upfront costs. |
| first_indexed | 2024-09-23T11:26:28Z |
| format | Article |
| id | mit-1721.1/128519 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T11:26:28Z |
| publishDate | 2020 |
| publisher | Springer Science and Business Media LLC |
| record_format | dspace |
| spelling | mit-1721.1/1285192022-09-27T19:32:29Z Economics of Beta-Cell Replacement Therapy Bandeiras, Cátia Hwa, Albert J. Cabral, Joaquim M. S. Ferreira, Frederico Castelo Finkelstein, Stan Neil Gabbay, Robert A. Massachusetts Institute of Technology. Institute for Data, Systems, and Society Purpose of Review: Type 1 diabetes impacts 1.3 million people in the USA with a total direct lifetime medical cost of $133.7 billion. Management requires a mix of daily exogenous insulin administration and frequent glucose monitoring. Decision-making by the individual can be burdensome. Recent Findings: Beta-cell replacement, which involves devices protecting cells from autoimmunity and allo-rejection, aims at restoring physiological glucose regulation and improving clinical outcomes in patients. Given the significant burden of T1D in the healthcare systems, cost-effectiveness analyses can drive innovation and policymaking in the area. Summary: This review presents the health economics analyses performed for donor-derived islet transplantation and the possible outcomes of stem cell-derived beta cells. Long-term cost-effectiveness of islet transplantation depends on the engraftment of these transplants, and the expenses and thresholds assumed by healthcare systems in different countries. Early health technology assessment analyses for stem cell-derived beta-cell replacement suggest manufacturing optimization is necessary to reduce upfront costs. 2020-11-18T16:54:00Z 2020-11-18T16:54:00Z 2019-08 2020-09-24T21:44:50Z Article http://purl.org/eprint/type/JournalArticle 1534-4827 1539-0829 https://hdl.handle.net/1721.1/128519 Bandeiras, Cátia et al. "Economics of Beta-Cell Replacement Therapy." Current Diabetes Reports 19, 9 (August 2019): 75 © 2019 Springer Science Business Media, LLC en https://doi.org/10.1007/s11892-019-1203-9 Current Diabetes Reports Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. Springer Science+Business Media, LLC, part of Springer Nature application/pdf Springer Science and Business Media LLC Springer US |
| spellingShingle | Bandeiras, Cátia Hwa, Albert J. Cabral, Joaquim M. S. Ferreira, Frederico Castelo Finkelstein, Stan Neil Gabbay, Robert A. Economics of Beta-Cell Replacement Therapy |
| title | Economics of Beta-Cell Replacement Therapy |
| title_full | Economics of Beta-Cell Replacement Therapy |
| title_fullStr | Economics of Beta-Cell Replacement Therapy |
| title_full_unstemmed | Economics of Beta-Cell Replacement Therapy |
| title_short | Economics of Beta-Cell Replacement Therapy |
| title_sort | economics of beta cell replacement therapy |
| url | https://hdl.handle.net/1721.1/128519 |
| work_keys_str_mv | AT bandeirascatia economicsofbetacellreplacementtherapy AT hwaalbertj economicsofbetacellreplacementtherapy AT cabraljoaquimms economicsofbetacellreplacementtherapy AT ferreirafredericocastelo economicsofbetacellreplacementtherapy AT finkelsteinstanneil economicsofbetacellreplacementtherapy AT gabbayroberta economicsofbetacellreplacementtherapy |